


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#16



APPLICANTS : Nadler, *et al.*
SERIAL NUMBER : 09/830,400 EXAMINER : Not Yet Assigned
FILING DATE : April 25, 2001 ART UNIT : 1642
FOR : CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR
ASSOCIATED ANTIGENS, SUCH AS THE TELOMERASE CATALYTIC SUBUNIT
(HTERT), AND METHODS FOR IDENTIFYING UNIVERSAL TUMOR ASSOCIATED
ANTIGENS

Box IDS
Commissioner for Patents
Washington, D.C. 20231

RECEIVED
FEB 19 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TECH CENTER 1600/2900

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed less than three months after the mailing date of the Supplementary Partial European Search Report for European application EP 99 956 777 that corresponds to the above-identified application. Accordingly, no fee or certification is believed due at this time.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is

considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 20363-015 NATL.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: February 11, 2003



Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/830,400
	Filing Date	April 25, 2001
	First Named Inventor	Nadler, et al.
	Group Art Unit	1642
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	20363-015 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date mm/dd/yyyy	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate mm/dd/yyyy

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No	
	B3	EP	1 093 381	Norsk Hydro ASA	04/25/2001		
	B4	WO	99/50392	Geron Corp.	10/07/1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C7	Brossart, et al. (1998). "Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes." <i>Cancer Research</i> . 58(4):732-736.
	C8	Jensen, et al. (1998). "A europium fluoroimmunoassay for measuring peptide binding to MHC class I molecules." <i>Journal of Immunological Methods</i> . 215(1-2):71-80.
	C9	Kawashima, et al. (1998). "The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors." <i>Human Immunology</i> . 59(1):1-14.
	C10	Kim, et al. (1994). "Specific association of human telomerase activity with immortal cells and cancer." <i>Science</i> . 266:2011-2015.
	C11	Schultze, et al. (1997). "CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy." <i>Journal of Clinical Investigation</i> . 100(11):2757-2765.
	C12	Schultze, et al. (1997). "Vaccination as immunotherapy for B cell lymphoma." <i>Hematological Oncology</i> . 15(3):129-139.
	C13	Vonderheide, et al. (1999). "Generation of telomerase-specific HLA-A3-restricted cytotoxic T lymphocytes from patient blood: implications for widely applicable anti-cancer immunotherapy." <i>Forty-first annual meeting of the American Society of Hematology</i> , New Orleans. 94(10):677a.
	C14	Supplementary Partial European Search Report for Application No. EP 99 95 6777. Mailed on 11/11/2002.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.